A dose escalating study of cabazitaxel (XRP6258) in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy

被引:1
|
作者
Villanueva, C. [1 ]
Awada, A. [2 ]
Campone, M. [3 ]
Machiels, J. P. [4 ]
Besse, T. [2 ]
Magherini, E. [5 ]
Dubin, F. [5 ]
Semiond, D. [5 ]
Pivot, X. [1 ]
机构
[1] Hop Jean Minjoz, F-25030 Besancon, France
[2] Inst Jules Bordet, B-1000 Brussels, Belgium
[3] Ctr Rene Gauducheau, F-44035 Nantes, France
[4] Clin Univ St Luc, Ctr Canc, B-1200 Brussels, Belgium
[5] Sanofi Aventis, Paris, France
来源
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词
D O I
10.1016/S1359-6349(09)70917-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:268 / 268
页数:1
相关论文
共 50 条
  • [41] Phase I study of capecitabine in combination with CPT-11 for metastatic breast cancer (MBC) pre-treated with anthracycline and taxanes
    Kashiwaba, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Phase II study of weekly gemcitabine in patients with metastatic breast cancer (mbc) relapsing or failing on both an anthracycline (A) and a taxane (T).
    Smorenburg, C
    Bontenbal, M
    Seynaeve, C
    van Zuylen, L
    de Heus, G
    Verweij, J
    de Wit, R
    ANNALS OF ONCOLOGY, 2000, 11 : 31 - 31
  • [43] Capecitabine (X) plus vinorelbine (N) as second-line therapy in Chinese patients (pts) with metastatic breast cancer (MBC).
    Xu, B
    Tian, L
    Wu, Q
    Zhou, M
    Wang, H
    Tong, Z
    Li, H
    Li, L
    Hu, G
    Shi, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 73S - 73S
  • [44] A randomized open-label, phase H study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2-amplified metastatic breast cancer (MBC) progressing after taxane treatment-GLICO-0801.
    Gomez, H. L.
    Neciosup, S. P.
    Neron do Nascimento, Y.
    Ismael, G.
    Barrios, C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] A phase II study of docetaxel (T) and capecitabine W combination chemotherapy as first-line chemotherapy for patients (pts) with metastatic breast cancer (MBC).
    Lim, HS
    Lee, HG
    Chun, JH
    Lee, JJ
    Lee, JS
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 100S - 100S
  • [46] Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from the Mexican Oncology Study Group.
    Torrecillas, L
    Soto, C
    Cervantes, G
    Benitez, H
    Acosta, A
    Cortes, P
    Gonzalez, F
    Zamora, R
    Rodriguez, G
    Silva, A
    Leoner, C
    Sauza, F
    Suarez, T
    Tokunaga, J
    Erazo, A
    Talavera, J
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S200 - S200
  • [47] Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
    Fumoleau, P
    Largillier, R
    Clippe, C
    Dièras, V
    Orfeuvre, H
    Lesimple, T
    Culine, S
    Audhuy, B
    Serin, D
    Curé, H
    Vuillemin, E
    Morère, JF
    Montestruc, F
    Mouri, Z
    Namer, M
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (04) : 536 - 542
  • [48] INTEGRATION OF CAPECITABINE (X) MONOTHERAPY WITH X COMBINATION THERAPY IN PATIENTS WITH METASTATIC BREAST CANCER (MBC): RATIONALE AND DESIGN OF X MAINTENANCE STUDY
    Wang, J.
    Xu, B.
    ANNALS OF ONCOLOGY, 2010, 21 : 120 - 120
  • [49] A phase II trial of combination therapy with capecitabine (C) and weekly paclitaxel (P) for metastatic breast cancer (MBC): Preliminary results in taxane-naive patients.
    Blum, JL
    Dees, C
    Negron, A
    McMahon, R
    Boehm, KA
    Asmar, L
    O'Shaughnessy, J
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S202 - S202
  • [50] Real world study on the efficacy and tolerability of ixabepilone monotherapy vs. combination therapy with capecitabine in metastatic breast cancer patients (MBC)
    Hyder, Tara
    Rosenzweig, Margaret
    Brufsky, Adam M.
    CANCER RESEARCH, 2021, 81 (04)